Uni-Bio Science Group Ltd. (0690) AI Stock Analysis

• Market Cap: HK$679.11M
• Dividend Yield: 2.29%
• Average Volume (3M): 6.01M
• Price to Earnings (P/E): 7.5
• Beta (1Y): -0.23
• Revenue Growth: 15.97%
• EPS Growth: -3.77%
• Country: HK
• Employees: 487
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.01
• Shares Outstanding: 5,971,228,000
• 10 Day Avg. Volume: 4,607,960
• 30 Day Avg. Volume: 6,013,203
• PEG Ratio: 0.21
• Price to Book (P/B): 1.13
• Price to Sales (P/S): 0.67
• P/FCF Ratio: 12.83
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 66 Neutral
• Price Target: HK$0.12 ▼(-6.15% Downside)

The stock score is primarily influenced by strong financial performance and attractive valuation. However, technical indicators suggest bearish momentum, which tempers the overall score. The absence of operating cash flows is a concern that needs monitoring.

Positive Factors

Revenue Growth

Consistent revenue growth indicates a strong market position and effective product adoption, supporting long-term business expansion.

Profitability

High profitability margins reflect efficient operations and cost control, enhancing the company's ability to reinvest and grow.

Balance Sheet Health

A strong balance sheet with low leverage provides financial stability and flexibility for future investments and growth opportunities.

Negative Factors

Cash Flow Concerns

The absence of operating cash flows could impact liquidity and limit the company's ability to fund operations and growth without external financing.

Earnings Decline

Declining EPS growth suggests challenges in maintaining profitability, which could affect investor confidence and future earnings potential.

Cash Management

Lack of cash flow data highlights potential issues in cash management, necessitating careful oversight to ensure financial health and operational continuity.

Uni-Bio Science Group Ltd. Business Overview & Revenue Model

Company Description

Uni-Bio Science Group Ltd. (0690) is a biotechnology company based in Hong Kong, primarily engaged in the research, development, manufacturing, and commercialization of high-quality biopharmaceutical products. The company focuses on the fields of oncology, autoimmune diseases, and other therapeutic areas, providing innovative solutions through its proprietary technologies and product pipelines. Uni-Bio Science is committed to enhancing patient care and improving health outcomes by delivering cutting-edge biopharmaceuticals and engaging in collaborations that expand its market reach.

How the Company Makes Money

Uni-Bio Science Group Ltd. generates revenue through multiple streams, focusing primarily on the sales of its biopharmaceutical products. The company earns income by marketing its proprietary drugs and therapies, particularly in oncology and autoimmune disease treatments, to healthcare providers and institutions. Additionally, Uni-Bio may engage in strategic partnerships and collaborations with other pharmaceutical companies, which can result in milestone payments, royalties based on sales, and co-development agreements. The company also explores licensing its technologies and products to other firms, further diversifying its revenue sources. Research grants and funding from governmental or non-governmental organizations may also contribute to its earnings, especially for ongoing research and development projects.

Uni-Bio Science Group Ltd. Financial Statement Overview

Summary

The company shows strong revenue growth and improving profitability, with a high gross profit margin and improved net profit margin. The balance sheet is stable with low leverage and strong equity. However, the absence of operating cash flows in 2024 raises concerns about cash generation capabilities.

Income Statement

The income statement shows a strong performance with consistent revenue growth, marked at 14.1% from 2023 to 2024, and improving profitability. The gross profit margin is high at 83.4% for 2024, indicating effective cost management. The net profit margin improved to 15.0% in 2024, reflecting increased efficiency. Both EBIT and EBITDA margins have shown positive trends, at 17.4% and 20.5% respectively, up from previous years.

Balance Sheet

The balance sheet reflects a stable financial position with a strong equity base. The debt-to-equity ratio remains low at 0.35, indicating low leverage. The equity ratio is robust at 62.9%, suggesting a healthy capital structure. Return on equity improved to 25.4% in 2024, showcasing efficient use of equity capital. Overall, the balance sheet demonstrates financial stability with potential for growth.

Cash Flow

Cash flow from operations is non-existent in 2024, which may raise concerns about cash generation capabilities. Historically, free cash flow showed positive growth, but recent results are unavailable. The absence of operating and free cash flow data in 2024 suggests a need for cautious monitoring of liquidity and cash management strategies.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	589.59M	552.98M	484.72M	440.32M	353.40M	208.78M
Gross Profit	484.56M	461.07M	392.82M	334.88M	277.01M	181.09M
EBITDA	122.21M	113.56M	93.56M	61.21M	1.31M	-49.95M
Net Income	91.35M	82.77M	70.88M	38.51M	-19.59M	-71.32M
Balance Sheet
Total Assets	556.05M	517.55M	409.99M	292.47M	267.59M	252.72M
Cash, Cash Equivalents and Short-Term Investments	170.51M	183.90M	129.24M	98.22M	83.61M	61.04M
Total Debt	108.00M	115.19M	56.30M	22.67M	5.60M	3.14M
Total Liabilities	173.20M	191.91M	152.82M	97.72M	93.29M	63.31M
Stockholders Equity	382.85M	325.64M	257.17M	194.75M	174.31M	189.41M
Cash Flow
Free Cash Flow	32.93M	28.71M	39.11M	20.23M	3.61M	-28.45M
Operating Cash Flow	70.93M	66.71M	98.85M	48.66M	12.04M	-15.47M
Investing Cash Flow	-45.62M	-168.07M	-76.14M	-27.03M	42.12M	-24.65M
Financing Cash Flow	-26.60M	27.79M	24.51M	2.58M	478.00K	-5.41M

Uni-Bio Science Group Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.13
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0690, the sentiment is Negative. The current price of 0.13 is above the 20-day moving average (MA) of 0.12, above the 50-day MA of 0.12, and above the 200-day MA of 0.11, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 34.27 is Neutral, neither overbought nor oversold. The STOCH value of 54.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0690.

Uni-Bio Science Group Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
0690	66 Neutral	HK$679.11M	7.45	26.27%	2.29%	15.97%	-3.77%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
2257	46 Neutral	HK$858.24M	―	―	―	―	83.89%
1244	41 Neutral	HK$1.30B	―	-21.45%	―	-8.43%	64.33%
2126	41 Neutral	HK$1.53B	-2.26	-51.56%	―	2.45%	2.58%
6628	41 Neutral	HK$1.17B	―	-34.18%	―	-57.84%	24.58%
9939	36 Underperform	HK$815.90M	-4.26	-54.87%	―	―	81.67%

Uni-Bio Science Group Ltd. Corporate Events

Uni-Bio Science Expands Global Reach of Osteoporosis Treatment Through Strategic Partnership

Uni-Bio Science Group Ltd. has announced a strategic partnership with Kexing Biopharm Co., Ltd. to commercialize its osteoporosis treatment, Bogutai®, in six countries including Saudi Arabia, Egypt, Morocco, Colombia, Argentina, and Mexico. This collaboration aims to tap into a market valued at nearly USD1.5 billion, leveraging Bogutai®’s success in China, where it achieved a 248.9% revenue growth in the first half of 2025. The partnership is expected to enhance Uni-Bio’s global expansion strategy, strengthen its position in the osteoporosis treatment market, and generate long-term value for shareholders.

Uni-Bio Science Group Reports Strong Growth and Strategic Milestones in H1 2025

Uni-Bio Science Group Ltd. reported a 13.4% increase in revenue and a 12.7% rise in profit for the first half of 2025, driven by strong product commercialization and cost efficiency. The company achieved significant milestones, including the approval of a new ophthalmology product and the acceptance of a marketing application for an antifungal treatment. Additionally, the launch of a high-end product series and a strategic focus on regenerative medicine signal the company’s commitment to innovation and market expansion.

Uni-Bio Science Group Schedules Board Meeting for Interim Financial Results

Uni-Bio Science Group Ltd. has announced an upcoming board meeting scheduled for August 28, 2025, to approve and publish the interim financial results for the first half of the year. This announcement signifies an important step in the company’s financial reporting process, potentially impacting its market position and providing insights into its operational performance for stakeholders.